Epione Medlab Co. Ltd. was founded in 2016 as a third-party medical laboratory focusing on molecular testing and pathology services, with a total laboratory area of more than 2,800 square meters. There are currently 65 employees, with 30% of them holding a master's degree or above. We have several technology platforms, including pathology analysis, quantitative nucleic acid analysis, circulating tumor cell analysis, high-throughput sequencing, mass spectrometry analysis, 10x single-cell sequencing, spatial multi-omics, and bioinformatics analysis, etc. We could flexibly adapt to different needs and provide one-stop solutions for our customers.
Epione Medlab was accredited by the College of American Pathologists (CAP) in 2021 for the first time and reaccredited with zero deficiencies in 2023.
MILESTONE
-
2017
Established, focusing on molecular testing and pathology services
-
2018
Roche-Epione Personalized Molecular Diagnostics Innovation Lab established
-
2019
Circulating Tumor Cell Detection Platform established
Honorary title of "High-tech Enterprise" granted -
2020
Shanghai third-party medical testing organization comprehensive assessment of A-level
-
2019-2022
We undergo the Shanghai Center for Clinical Laboratory inspection, clinical pathology quality control on-site inspection yearly, and are highly recognized by experts.
We participate and pass with excellent results in various quality assessment activities held by the National Ministry of Health Center for Clinical Laboratory and Shanghai Center for Clinical Laboratory yearly. -
2021
First time CAP accreditation with full scores on multiple proficiency tests
-
2023
Re-accredited by CAP with zero deficiency
QUALIFICATION
Our Advantages
